Assoc. Prof. Graham Pidgeon
Associate Professor, Surgery
- Research Institute:
Department of Surgery; Trinity Translational Medicine Institute (TTMI)
- Contact e-mail:
- Research Area(s):
Angiogenesis; Anticancer therapies; Apoptosis; Apoptosis, molecular control; Biological Markers; Breast cancer; Cancer Biology; Cancer genetics and cell biology including metastasis; Cancer/Carcinogenesis; Cardiology; Cardiovascular and molecular pharmacology; Cardiovascular disease, pharmacology; Cardiovascular Diseases; Cardiovascular regulation and hypertension; Cardiovascular System; Cell Communication; Cell Components; Cell cycle control; Cell Lines; Clinical research, trials; Coronary artery ischaemia; Cytoskelton, cell division; DNA transcription and translation; Drug development and evaluation; Extracellular Matrix; Gene therapy; Gene transcription in human cancer; Genomic structure and function, molecular approaches to gene function; Growth Factors; Immunology; Inflammation and coagulation syndromes; Intra and intercellular signalling; Lipids, steroids, membranes; Lung Cancer; Metabolism, Lipid; Molecular Biology; Molecular Genetics; Nutrition/Dietetics; Oncogenes, apoptosis and tumour development; Oncology; Pathogenesis; Pathology; Pharmacology; Platelet activating agents; Prostaglandins; Prostate cancer; Proteomics; Pulmonary Diseases; Radiotherapy, Biological response modifiers and chemoprevention; Receptors; Regulatory methods of gene expression; Respiratory System; Therapeutic and Clinical oncology; Thrombosis; Thrombosis and haemostasis; Tissue Culture; Transgenic Animals; Tumour immunology and immunotherapy; Vascular Biology; Vascular Biology, Thrombosis.
Research Description:
His current research is focused on the role of bioactive lipid enzymes including cycloxygenase and lipoxygenase in the growth and metastasis of lung and oesophageal cancer. Dr. Graham Pidgeon's group have a strong interest in the molecular processes regulating the growth and survival of oesophageal and lung cancer. Work in the past months has concentrated on the development of an adipose biobank from patients undergoing oesophageal and colorectal resections, to investigate the role of visceral fat in the progression of these malignancies. The group are prospectively investigating the incidence of central adiposity, metabolic syndrome and adipocyte secretion amongst newly diagnosed patients with these cancers to determine the link between these parameters and tumour size, metastases, treatment pathways, and survival.
